nach oben

Erschienen in:

01.06.2012 | Reviews

Updated Report on Comparative Effectiveness of ACE inhibitors, ARBs, and Direct Renin Inhibitors for Patients with Essential Hypertension: Much More Data, Little New Information

verfasst von: Benjamin J. Powers, MD, MHS, Remy R. Coeytaux, M.D., Ph.D., Rowena J. Dolor, M.D., M.H.S., Vic Hasselblad, Ph.D., Uptal D. Patel, M.D., William S. Yancy Jr., M.D., MHS, Rebecca N. Gray, D. Phil., R. Julian Irvine, M.C.M., Amy S. Kendrick, R.N, M.S.N, Gillian D. Sanders, PhD

Erschienen in: Journal of General Internal Medicine | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

OBJECTIVES

A 2007 systematic review compared angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in patients with hypertension. Direct renin inhibitors (DRIs) have since been introduced, and significant new research has been published. We sought to update and expand the 2007 review.

DATA SOURCES

We searched MEDLINE and EMBASE (through December 2010) and selected other sources for relevant English-language trials.

STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS

We included studies that directly compared ACE inhibitors, ARBs, and/or DRIs in at least 20 total adults with essential hypertension; had at least 12 weeks of follow-up; and reported at least one outcome of interest. Ninety-seven (97) studies (36 new since 2007) directly comparing ACE inhibitors versus ARBs and three studies directly comparing DRIs to ACE inhibitor inhibitors or ARBs were included.

STUDY APPRAISAL AND SYNTHESIS METHODS

A standard protocol was used to extract data on study design, interventions, population characteristics, and outcomes; evaluate study quality; and summarize the evidence.

RESULTS

In spite of substantial new evidence, none of the conclusions from the 2007 review changed. The level of evidence remains high for equivalence between ACE inhibitors and ARBs for blood pressure lowering and use as single antihypertensive agents, as well as for superiority of ARBs for short-term adverse events (primarily cough). However, the new evidence was insufficient on long-term cardiovascular outcomes, quality of life, progression of renal disease, medication adherence or persistence, rates of angioedema, and differences in key patient subgroups.

LIMITATIONS

Included studies were limited by follow-up duration, protocol heterogeneity, and infrequent reporting on patient subgroups.

CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS

Evidence does not support a meaningful difference between ACE inhibitors and ARBs for any outcome except medication side effects. Few, if any, of the questions that were not answered in the 2007 report have been addressed by the 36 new studies. Future research in this area should consider areas of uncertainty and be prioritized accordingly.

Nur mit Berechtigung zugänglich

Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38.PubMedCrossRef

Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.[Erratum appears in Lancet. 2003 Mar 22;361(9362):1060]. Lancet. 2002;360(9349):1903–13.PubMedCrossRef

Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026–33.PubMedCrossRef

Matchar DB, McCrory DC, Orlando LA, et al. Comparative Effectiveneness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Comparative Effectiveness Review No. 10. (Prepared by Duke Evidence-based Practice Center under Contract No. 290-02-0025.) Rockville, MD: Agency for Healthcare Research and Quality. November 2007. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed October 31, 2010.

Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148(1):16–29.PubMed

Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Comparative Effectiveness Review No. 34. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 11-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. June 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed October 31, 2011.

Anonymous. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. York, UK: NHS Centre for Reviews and Dissemination. 2001 Mar. Report No.: CRD Report No. 4 (2nd edition).

Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21–35.PubMedCrossRef

Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions–Agency for Healthcare Research and Quality and the Effective Health-Care Program. J Clin Epidemiol. 2010;63(5):513–23.PubMedCrossRef

10.

Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.PubMedCrossRef

11.

Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26(3):589–99.PubMedCrossRef

12.

Andersen K, Weinberger MH, Constance CM, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. JRAAS - J Renin-Angiotensin-Aldosterone Syst. 2009;10(3):157–67.CrossRef

13.

Duprez DA, Munger MA, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: A randomized controlled trial. J Hum Hypertens. 2010;24(9):600–8. Epub 2009 Dec 24.PubMedCrossRef

14.

Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530–7.PubMedCrossRef

15.

Akat PB, Bapat TR, Murthy MB, et al. Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension. Indian J Pharmacol. 2010;42(3):153–6.PubMedCrossRef

16.

Amerena J, Pappas S, Ouellet JP, et al. ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res. 2002;30(6):543–52.PubMed

17.

Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15(1):9–14.PubMedCrossRef

18.

Breeze E, Rake EC, Donoghue MD, et al. Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension. J Hum Hypertens. 2001;15(12):857–62.PubMedCrossRef

19.

Elliott WJ. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. J Hum Hypertens. 1999;13(6):413–7.PubMedCrossRef

20.

Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15(1):15–24.PubMedCrossRef

21.

Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15(1):25–32.PubMedCrossRef

22.

Avanza ACJ, El Aouar LM, Mill JG. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arq Bras Cardiol. 2000;74(2):103–17.PubMed

23.

Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.[erratum appears in N Engl J Med. 2005 Apr 21;352(16)1731]. N Engl J Med. 2004;351(19):1952–61.PubMedCrossRef

24.

Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11(8):483–9.PubMedCrossRef

25.

Celik T, Iyisoy A, Kursaklioglu H, et al. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. Clin Cardiol. 2005;28(6):298–302.PubMedCrossRef

26.

Coca A, Calvo C, Garcia-Puig J, et al. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorizacion Ambulatoria Presion Arterial APROVEL). Clin Ther. 2002;24(1):126–38.PubMedCrossRef

27.

Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002;20(11):2293–300.PubMedCrossRef

28.

De Rosa ML, Cardace P, Rossi M, et al. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens. 2002;16(2):133–40.PubMedCrossRef

29.

Derosa G, Cicero AF, Ciccarelli L, et al. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther. 2003;25(7):2006–21.PubMedCrossRef

30.

Deyneli O, Yavuz D, Velioglu A, et al. Effects of ACE inhibition and angiotension II receptor blockade on glomerular basement membrane protein excretion and change selectivity in type 2 diabetic patients. JRAAS - J Renin-Angiotensin-Aldosterone Syst. 2006;7(2):98–103.CrossRef

31.

Eguchi K, Kario K, Shimada K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am J Cardiol. 2003;92(5):621–4.PubMedCrossRef

32.

Fernandez-Campo L, Grande MT, Diego J, et al. Effect of different antihypertensive treatments on Ras, MAPK and Akt activation in hypertension and diabetes. Clin Sci. 2009;116(2):165–73.PubMedCrossRef

33.

Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15(4 Pt 1):316–20.PubMedCrossRef

34.

Fogari R, Mugellini A, Zoppi A, et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol. 2004;59(12):863–8.PubMedCrossRef

35.

Fogari R, Zoppi A, Preti P, et al. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens. 2001;14(9 Pt 1):921–6.PubMedCrossRef

36.

Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006;20(3):177–85.PubMedCrossRef

37.

Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 2008;21(9):1034–9.PubMedCrossRef

38.

Formosa V, Bellomo A, Iori A, et al. The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly. Arch Gerontol Geriatr. 2009;49(Suppl 1):95–101.PubMedCrossRef

39.

Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens. 1997;11(Suppl 2):S61–2.PubMed

40.

Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41(6):1281–6.PubMedCrossRef

41.

Guntekin U, Gunes Y, Tuncer M, et al. Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients. Adv Ther. 2008;25(8):775–86.PubMedCrossRef

42.

Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. 2002;16(8):569–75.PubMedCrossRef

43.

Hermida RC, Ayala DE, Khder Y, et al. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther. 2008;30(1):108–20.PubMedCrossRef

44.

Hosohata K, Saito S, Asayama K, et al. Progress report on The Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) study: status at February 2004. Clin Exp Hypertens (New York). 2007;29(1):69–81.CrossRef

45.

Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999;17(2):293–302.PubMedCrossRef

46.

Kavgaci H, Sahin A, Onder Ersoz H, et al. The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. Diabetes Res Clin Pract. 2002;58(1):19–25.PubMedCrossRef

47.

Kloner RA, Neutel J, Roth EM, et al. Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. Ann Pharmacother. 2008;42(11):1552–62.PubMedCrossRef

48.

Koylan N, Acarturk E, Canberk A, et al. Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: a multicenter, open-labeled, three-armed study. Blood Press Suppl. 2005;1:23–31.PubMedCrossRef

49.

Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58(2):762–9.PubMedCrossRef

50.

Lacourciere Y, Neutel JM, Davidai G, et al. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006;19(1):104–12.PubMedCrossRef

51.

Larochelle P, Flack JM, Marbury TC, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol. 1997;80(12):1613–5.PubMedCrossRef

52.

Malacco E, Santonastaso M, Vari NA, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.[erratum appears in Clin Ther. 2004 Jul;26(7):1185]. Clin Ther. 2004;26(6):855–65.PubMedCrossRef

53.

Malacco E, Omboni S, Volpe M, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: The ESPORT study. J Hypertens. 2010;28(11):2342–50.PubMedCrossRef

54.

Mallion JM, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens, Suppl. 1995;13(1):S35–41.CrossRef

55.

Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens. 2000;13(5 Pt 1):504–11.PubMedCrossRef

56.

Matsuda H, Hayashi K, Saruta T. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. J Hum Hypertens. 2003;17(4):271–6.PubMedCrossRef

57.

McInnes GT, O'Kane KP, Istad H, et al. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000;14(4):263–9.PubMedCrossRef

58.

Menne J, Farsang C, Deak L, et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens. 2008;26(9):1860–7.PubMedCrossRef

59.

Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens. 1998;12(3):203–8.PubMedCrossRef

60.

Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440–4.PubMedCrossRef

61.

Naidoo DP, Sareli P, Marin F, et al. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. Adv Ther. 1999;16(5):187–99.PubMed

62.

Nakamura T, Kawachi K, Saito Y, et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Hear J. 2009;50(4):501–12.CrossRef

63.

Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther. 1999;6(3):161–6.PubMedCrossRef

64.

Nielsen S, Dollerup J, Nielsen B, et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant. 1997;12(Suppl 2):19–23.PubMed

65.

Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 1995;13(11):1343–51.PubMedCrossRef

66.

Onal IK, Altun B, Onal ED, et al. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med. 2009;20(4):369–72.PubMedCrossRef

67.

Rabbia F, Silke B, Carra R, et al. Heart rate variability and baroreflex sensitivity during fosinopril, irbesartan and atenolol therapy in hypertension. Clin Drug Investig. 2004;24(11):651–9.PubMedCrossRef

68.

Ragot S, Ezzaher A, Meunier A, et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens. 2002;16(12):865–73.PubMedCrossRef

69.

Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens. 2003;16(6):439–44.PubMedCrossRef

70.

Rehman A, Ismail SB, Naing L, et al. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among Malayhypertensive subjects with a known genetic profile. Am J Hypertens. 2007;20(2):184–9.PubMedCrossRef

71.

Robles NR, Angulo E, Grois J, et al. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. Ren Fail. 2004;26(4):399–404.PubMedCrossRef

72.

Roca-Cusachs A, Oigman W, Lepe L, et al. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Acta Cardiol. 1997;52(6):495–506.PubMed

73.

Rosei EA, Rizzoni D, Muiesan ML, et al. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens. 2005;23(2):435–44.PubMedCrossRef

74.

Ruff D, Gazdick LP, Berman R, et al. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens. 1996;14(2):263–70.PubMedCrossRef

75.

Ruilope L, Jager B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. 2001;10(4):223–9.PubMedCrossRef

76.

Saito S, Asayama K, Ohkubo T, et al. The second progress report on the Hypertension Objective treatment based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) study. Blood Press Monit. 2004;9(5):243–7.PubMedCrossRef

77.

Sanchez RA, Masnatta LD, Pesiney C, et al. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens. 2008;26(12):2393–8.PubMedCrossRef

78.

Scaglione R, Argano C, Di Chiara T, et al. Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients. J Hum Hypertens. 2007;21(4):307–15.PubMed

79.

Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44(2):362–8.PubMedCrossRef

80.

Schram MT, van Ittersum FJ, Spoelstra-de Man A, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens. 2005;19(6):429–37.PubMedCrossRef

81.

Sengul AM, Altuntas Y, Kurklu A, et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract. 2006;71(2):210–9.PubMedCrossRef

82.

Shand BI. Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension. J Hum Hypertens. 2000;14(5):305–9.PubMedCrossRef

83.

Shand BI, Lynn KL. A comparative study of losartan and enalapril on erythropoiesis and renal function in hypertensive patients with renal parenchymal disease. Clin Nephrol. 2000;54(5):427–8.PubMed

84.

Shibasaki Y, Masaki H, Nishiue T, et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron. 2002;90(3):256–61.PubMedCrossRef

85.

Sonoda M, Aoyagi T, Takenaka K, et al. A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Hear J. 2008;49(1):95–103.CrossRef

86.

Souza-Barbosa LA, Ferreira-Melo SE, Ubaid-Girioli S, et al. Endothelial vascular function in hypertensive patients after renin-angiotensin system blockade. J Clin Hypertens. 2006;8(11):803–9. quiz 10–1.CrossRef

87.

Spinar J, Vitovec J, Soucek M, et al. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitrni Lekarstvi. 2009;55(5):481–8.PubMed

88.

Spoelstra-de Man AM, van Ittersum FJ, Schram MT, et al. Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. J Hum Hypertens. 2006;20(8):599–611.PubMedCrossRef

89.

Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens. 2006;8(9):634–41.CrossRef

90.

Townsend R, Haggert B, Liss C, et al. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 1995;17(5):911–23.PubMedCrossRef

91.

Uchiyama-Tanaka Y, Mori Y, Kishimoto N, et al. Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension. Kidney & Blood Press Res. 2005;28(2):111–6.CrossRef

92.

Verdecchia P, Schillaci G, Reboldi GP, et al. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study. Blood Press Monit. 2000;5(3):187–93.PubMedCrossRef

93.

Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health & Risk Manag. 2007;3(6):999–1005.

94.

Williams B, Gosse P, Lowe L, et al. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24(1):193–200.PubMedCrossRef

95.

Xu D, Liu J, Ji C, et al. Effects of telmisartan on hypertensive patients with dyslipidemia and insulin resistance. J of Geriatr Cardiol. 2007;4(3):149–52.

96.

Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology. 2007;12(2):147–53.PubMedCrossRef

97.

Zhu S, Liu Y, Wang L, et al. Transforming growth factor-(beta)(1) is associated with kidney damage in patients with essential hypertension: Renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant. 2008;23(9):2841–6.PubMedCrossRef

98.

Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23(11):2093–100.PubMedCrossRef

99.

Cotter J, Oliveira P, Cunha P, et al. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system. Rev Port Cardiol. 2008;27(11):1395–404.PubMed

100.

Delea TE, Taneja C, Moynahan A, et al. Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. Am J Health Syst Pharm. 2007;64(11):1187–96.PubMedCrossRef

101.

Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol. 2007;98(1):57–63.PubMedCrossRef

102.

Ozturk S, Sar F, Bengi-Bozkurt O, et al. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis. Kidney Blood Press Res. 2009;32(4):268–75.PubMedCrossRef

103.

Sato A, Tabata M, Hayashi K, et al. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. Clin Exp Nephrol. 2003;7(3):215–20.PubMedCrossRef

104.

Gregoire JP, Moisan J, Guibert R, et al. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther. 2001;23(5):715–26.PubMedCrossRef

105.

Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol. 1999;47(1):111–4.PubMedCrossRef

106.

Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20(4):671–81.PubMedCrossRef

107.

Bourgault C, Senecal M, Brisson M, et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens. 2005;19(8):607–13.PubMedCrossRef

108.

Burke TA, Sturkenboom MC, Lu SE, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006;24(6):1193–200.PubMedCrossRef

109.

Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther. 2001;23(12):1999–2010.PubMedCrossRef

110.

Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002;16(6):439–44.PubMedCrossRef

111.

Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther. 2002;24(8):1347–57. discussion 6.PubMedCrossRef

112.

Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14(11):795–803.PubMedCrossRef

113.

Marentette MA, Gerth WC, Billings DK, et al. Antihypertensive persistence and drug class. Can J Cardiol. 2002;18(6):649–56.PubMed

114.

Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Managed Care Pharm. 2003;9(5):424–9.

115.

Hasford J, Schroder-Bernhardi D, Rottenkolber M, et al. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007;63(11):1055–61.PubMedCrossRef

116.

Lachaine J, Petrella RJ, Merikle E, et al. Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data. Can J Cardiol. 2008;24(4):269–73.PubMedCrossRef

117.

Patel BV, Remigio-Baker RA, Mehta D, et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens. 2007;9(9):692–700.CrossRef

118.

Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004–2006. Med J Aust. 2008;188(4):224–7.PubMed

119.

Meltzer D, Basu A, Conti R. The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research. PharmacoEconomics. 2010;28(10):843–53.PubMedCrossRef

120.

Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med. 2009;151(12):861–71.PubMed

121.

Califf RM, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–90.PubMedCrossRef

122.

Dream Trial Investigators, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–62.PubMedCrossRef

123.

Jong P, Demers C, McKelvie RS, et al. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2002;39(3):463–70.PubMedCrossRef

124.

Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J. 2008;155(5):791–805.PubMedCrossRef

125.

Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627–36.PubMedCrossRef

126.

Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085–95.PubMed

Titel: Updated Report on Comparative Effectiveness of ACE inhibitors, ARBs, and Direct Renin Inhibitors for Patients with Essential Hypertension: Much More Data, Little New Information
verfasst von: Benjamin J. Powers, MD, MHS
Remy R. Coeytaux, M.D., Ph.D.
Rowena J. Dolor, M.D., M.H.S.
Vic Hasselblad, Ph.D.
Uptal D. Patel, M.D.
William S. Yancy Jr., M.D., MHS
Rebecca N. Gray, D. Phil.
R. Julian Irvine, M.C.M.
Amy S. Kendrick, R.N, M.S.N
Gillian D. Sanders, PhD
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Journal of General Internal Medicine / Ausgabe 6/2012
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-011-1938-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

OBJECTIVES

DATA SOURCES

STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS

STUDY APPRAISAL AND SYNTHESIS METHODS

RESULTS

LIMITATIONS

CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

Older Adults’ Mental Health Function and Patient-Centered Care: Does the Presence of a Family Companion Help or Hinder Communication?

Delaying Blood Pressure Control in Type 2 Diabetes: Illustrating Principles in the Practice of Medicine

Is It Time for a Blood Pressure Measurement “Bundle”?

A 60-Year-Old Woman with Chorea and Weight Loss

From the Editors’ Desk: Why NCATS Should Read this Issue of JGIM